<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-120320" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pharmacologic Therapy for Obesity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname> Rodrigues Silva Sombra</surname>
            <given-names>Lorenna</given-names>
          </name>
          <aff>Albert Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lorenna Rodrigues Silva Sombra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-120320.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Obesity, a metabolic disease characterized by excessive adipose tissue, is a global epidemic affecting individuals of all ages. Classified by body mass index (BMI), it poses significant health risks, including diabetes, hypertension, hyperlipidemia, arthritis, sleep apnea, and cancer. Given its chronic nature and associated morbidity and mortality, prompt diagnosis and treatment are essential.</p>
        <p>This activity will cover updates on recent advancements in pharmacologic therapies, focusing on their efficacy not only in weight loss but also in managing diabetes and improving cardiovascular health. The interprofessional approach to evaluating and treating obesity will be highlighted, emphasizing the importance of lifestyle modifications, medication, and, when necessary, bariatric surgery. Overall, clinicians will acquire valuable insights into the latest strategies for addressing obesity and its related health issues, enabling them to enhance patient care and outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify individuals at risk for obesity-related complications based on comprehensive assessments of BMI, medical history, and associated comorbidities.</p></list-item><list-item><p>Screen patients for suitability and eligibility for pharmacologic treatment, considering contraindications, previous medical history, and risk factors.</p></list-item><list-item><p>Implement evidence-based pharmacologic interventions as part of a multidisciplinary approach to manage obesity, integrating medications into a comprehensive treatment plan.</p></list-item><list-item><p>Coordinate long-term care plans, ensuring continuity and addressing challenges related to weight maintenance and potential side effects of pharmacologic interventions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=120320&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=120320">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-120320.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Obesity is a pervasive chronic disease&#x000a0;that continues to rise&#x000a0;in prevalence globally,&#x000a0;affecting not&#x000a0;just&#x000a0;adults but also adolescents and children. It has reached epidemic proportions and is now recognized as a significant health crisis.<xref ref-type="bibr" rid="article-120320.r1">[1]</xref></p>
        <p>Epidemiological studies have defined obesity using the body mass index (BMI), calculated by dividing a person's weight in kilograms by the square of their height in meters.&#x000a0;This method&#x000a0;enables the&#x000a0;stratification of obesity-related health risks&#x000a0;within populations. A&#x000a0;BMI exceeding&#x000a0;30 kg/m&#x000b2; is considered diagnostic for obesity and is further subclassified into class 1 (30&#x000a0;to 34.9 kg/m&#x000b2;), class 2 (35&#x000a0;to 39.9 kg/m&#x000b2;), and class&#x000a0;3, known as morbid obesity (&#x02265;40 kg/m&#x000b2;).</p>
        <p>The primary approach&#x000a0;to addressing obesity&#x000a0;involves promoting weight loss&#x000a0;through behavioral therapy,&#x000a0;encompassing dietary changes, and adopting a healthy lifestyle with regular physical activity. Weight loss significantly reduces cardiovascular risk factors, aids disease prevention, and&#x000a0;enhances&#x000a0;self-esteem and overall functionality. While significant weight loss produces benefits in overall mortality, moderate&#x000a0;weight loss (5%-10%),&#x000a0;achievable&#x000a0;through lifestyle modifications and medications, has been&#x000a0;shown to significantly&#x000a0;improve&#x000a0;various conditions, including type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, nonalcoholic fatty liver disease, osteoarthritis, cancer, and sleep apnea.<xref ref-type="bibr" rid="article-120320.r2">[2]</xref><xref ref-type="bibr" rid="article-120320.r3">[3]</xref><xref ref-type="bibr" rid="article-120320.r4">[4]</xref></p>
        <p>In addition to these measures,&#x000a0;given&#x000a0;the challenges&#x000a0;associated with weight&#x000a0;loss and its maintenance, evidence-based pharmacologic therapy&#x000a0;is often deemed necessary to&#x000a0;achieve a&#x000a0;more effective and sustained response in managing obesity. Healthcare providers&#x000a0;are essential in engaging in a&#x000a0;shared decision-making process with patients, carefully considering&#x000a0;the risks and benefits. This collaborative approach ensures the selection of the most appropriate pharmacotherapy that aligns with the patient's profile.&#x000a0;</p>
        <p>When these methods prove ineffective, or if there is an urgent&#x000a0;need for weight loss and pharmacotherapy has not yielded the desired results, bariatric surgery can be considered. Bariatric surgery has demonstrated significant improvements in morbidity and mortality. Notably, patients who have previously failed to engage in a weight loss program or refuse assistance in a behavioral program are at a high&#x000a0;risk of&#x000a0;relapse following bariatric surgery. Therefore, surgical intervention may not be the recommended course of action in such cases.</p>
      </sec>
      <sec id="article-120320.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>This&#x000a0;activity aims to assess the existing evidence regarding&#x000a0;currently available weight loss medications and examine substances that&#x000a0;lack proven benefits or could be harmful, leading to their discontinuation.&#x000a0;</p>
        <p>Obesity is a&#x000a0;widely discussed&#x000a0;topic,&#x000a0;with a&#x000a0;growing body of literature&#x000a0;exploring the effectiveness of multiple compounds in its treatment. However, limited evidence supports either the&#x000a0;endorsement or cessation&#x000a0;of various substances and dietary supplements. Consequently,&#x000a0;patients&#x000a0;persist in buying over-the-counter compounds, unaware that some can&#x000a0;be potentially&#x000a0;harmful.&#x000a0;</p>
        <p>Clinicians&#x000a0;must caution&#x000a0;patients about the potential risks associated with weight-loss supplements and&#x000a0;carefully monitor&#x000a0;those&#x000a0;who use them. The&#x000a0;conclusions drawn from a 2015 review regarding some of these supplements&#x000a0;are outlined below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Green tea,&#x000a0;<italic toggle="yes">Garcinia cambogia,</italic>&#x000a0;conjugated linoleic acid, and chitosan&#x000a0;exhibited no&#x000a0;significant impact&#x000a0;on weight loss, indicating that healthcare professionals should not endorse their use.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Data on the effectiveness of&#x000a0;chromium,&#x000a0;Gambisan,&#x000a0;<italic toggle="yes">Hoodia gordonii</italic>, and&#x000a0;<italic toggle="yes">Cynanchum auriculatum</italic>&#x000a0;are inconclusive. Therefore,&#x000a0;clinicians should&#x000a0;refrain from recommending their use due to the lack of evidence and the potential risk of harm.<xref ref-type="bibr" rid="article-120320.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Human chorionic gonadotropin (hCG) has been promoted as a potential weight loss therapy; however, clinical trials&#x000a0;do not support its efficacy. Several randomized trials have demonstrated that hCG injections or pills, when combined with a very low-calorie diet&#x000a0;(500 kcal/d), are&#x000a0;no more effective than a placebo in treating obesity.<xref ref-type="bibr" rid="article-120320.r6">[6]</xref>&#x000a0;The weight loss effect&#x000a0;is solely correlated to caloric restriction. Notably, very low-calorie diets are not&#x000a0;sustainable in the long term compared to conventional diets because&#x000a0;people tend to regain weight&#x000a0;rapidly upon discontinuing&#x000a0;such diets, and their&#x000a0;impact on other aspects of health remains unclear.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sibutramine was withdrawn from the US and European markets in 2010&#x000a0;following the Sibutramine Cardiovascular Outcomes (SCOUT)&#x000a0;trial, which revealed&#x000a0;a 16% increase in cardiovascular events in the medication group (11.4% versus 10% in the placebo). The Food and Drug Administration (FDA)&#x000a0;determined that the risks outweighed the benefits. Notably, the study population&#x000a0;included individuals aged&#x000a0;55 years or older who were overweight or obese and&#x000a0;had a history of cardiovascular disease or type 2 diabetes mellitus, along with&#x000a0;one additional cardiovascular risk factor.<xref ref-type="bibr" rid="article-120320.r7">[7]</xref> In some countries, sibutramine is still prescribed&#x000a0;to patients&#x000a0;who do not&#x000a0;meet any of the above criteria but under strict supervision and regulation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lorcaserin, another regulated weight-loss medication, was withdrawn in February 2020. This decision followed a safety clinical trial&#x000a0;involving 12,000 patients, which revealed a higher incidence of various types of cancer compared to the placebo group (7.7% versus 7.1% of patients), with the most common cancers being&#x000a0;pancreatic, colorectal, and lung cancer.&#x000a0;The FDA has not suggested any&#x000a0;specific cancer screening&#x000a0;for individuals&#x000a0;previously on lorcaserin apart from&#x000a0;age-appropriate screening protocols.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120320.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Sustained weight loss is rarely achievable solely through decreased food intake and increased energy expenditure due to counteractive adaptive biological responses.<xref ref-type="bibr" rid="article-120320.r8">[8]</xref><xref ref-type="bibr" rid="article-120320.r9">[9]</xref>&#x000a0;Decreases&#x000a0;in energy expenditure rates and increases in appetite&#x000a0;following weight loss are linked to&#x000a0;hormonal changes that&#x000a0;encourage weight regain.&#x000a0;</p>
        <p>Despite&#x000a0;the challenges these adaptive mechanisms pose hindering&#x000a0;sustained weight loss, the recommendation&#x000a0;remains that all individuals adopt a healthy, well-balanced eating pattern. Ideally, this should be supervised,&#x000a0;coupled with maintaining a regular physical activity routine of at least 30 to 60 minutes of aerobic activity on most days of the week. This approach aids in&#x000a0;achieving weight and fat loss,&#x000a0;improving&#x000a0;cardiometabolic parameters, and supporting long-term weight maintenance.<xref ref-type="bibr" rid="article-120320.r10">[10]</xref></p>
        <p>
<bold>Nonpharmacologic Therapy</bold>
</p>
        <p><bold>Lifestyle intervention</bold>&#x000a0;is paramount. Before starting weight loss drug therapy, it is important to establish a lifestyle intervention program,&#x000a0;preferably under&#x000a0;the close supervision&#x000a0;of a dietitian,&#x000a0;with long-term follow-up akin to that in&#x000a0;extended trials.<xref ref-type="bibr" rid="article-120320.r11">[11]</xref><xref ref-type="bibr" rid="article-120320.r12">[12]</xref>&#x000a0;While&#x000a0;discussing various lifestyle interventions is beyond the scope of this article, which focuses on medication therapy, it is important to note that pharmacologic therapy should be&#x000a0;considered&#x000a0;only after optimizing all nonpharmacologic approaches.</p>
        <p><bold>Dietary</bold>
<bold>adherence</bold> is essential for weight loss, regardless of the chosen diet. A study comparing&#x000a0;various types of diets found that the outcomes were directly proportional to the level of adherence exhibited by participants.<xref ref-type="bibr" rid="article-120320.r13">[13]</xref>&#x000a0;</p>
        <p><bold>Very low-calorie diets</bold> can provide faster initial weight loss; however, the body's hormonal adaptation proves challenging to&#x000a0;sustain long-term. Following&#x000a0;a dietary&#x000a0;plan that&#x000a0;maintains&#x000a0;a negative calorie balance in the long term is essential.&#x000a0;Initiating medication therapy&#x000a0;can help overcome the stagnation&#x000a0;often observed after the initial months of diet and lifestyle intervention.&#x000a0;</p>
        <p><bold>Intermittent fasting</bold> dietary patterns can be considered a&#x000a0;viable alternative, although studies have shown inconsistent efficacy. In a 1-year trial with 100 individuals with obesity, 3 groups were compared:&#x000a0;alternate-day fasting (patients alternated 25% of total energy consumed on fasting&#x000a0;days and 125% on free days) versus caloric restriction (ingesting 75% of total energy needs daily) versus nonintervention control. After 6 and 12 months, mean weight loss was comparable&#x000a0;for individuals in the alternate fasting group (-6.8% [95% CI, -9.1% to -4.5%] and -6.0% [95% CI, -8.5% to -3.6%, respectively]) and the daily constant calorie restriction group (-6.8% [95% CI, -9.1% to -4.6%] and&#x000a0;-5.3% [95% CI, -7.6% to -3.0%], respectively), when compared to the control group,&#x000a0;indicating similar efficacy.<xref ref-type="bibr" rid="article-120320.r14">[14]</xref></p>
        <p>Regardless of the diet or lifestyle program, continuous surveillance and follow-ups are essential. As&#x000a0;obesity&#x000a0;is a chronic disease with adaptative mechanisms, ongoing monitoring is mandatory to ensure better long-term outcomes.&#x000a0;</p>
        <p><bold>Exercise</bold>&#x000a0;is vital in maintaining a negative calorie balance by&#x000a0;increasing energy expenditure through physical activity and aiding in weight loss.&#x000a0;A 2017 study&#x000a0;highlighted that aerobic and anaerobic exercises combined&#x000a0;prove more efficient for weight loss than either type of exercise in isolation.<xref ref-type="bibr" rid="article-120320.r15">[15]</xref><xref ref-type="bibr" rid="article-120320.r16">[16]</xref>&#x000a0;The recommended guideline suggests engaging in approximately 30 minutes or more of exercise,&#x000a0;5 to&#x000a0;7 days a week, to prevent weight gain and&#x000a0;enhance&#x000a0;cardiovascular health&#x000a0;in adults.<xref ref-type="bibr" rid="article-120320.r17">[17]</xref>&#x000a0;</p>
        <p><bold>Behavior&#x000a0;therapy</bold>&#x000a0;is crucial in&#x000a0;assisting patients with long-term changes in their eating&#x000a0;habits. This approach&#x000a0;involves&#x000a0;modifying and monitoring food intake, adapting&#x000a0;physical activity, and controlling environmental stimuli that trigger binge eating. Individuals&#x000a0;are aided in&#x000a0;developing healthier eating behaviors and sustaining long-lasting lifestyle changes.&#x000a0;</p>
        <p>
<bold>Pharmacologic Therapy</bold>
</p>
        <p>Initiating approved weight loss medications can be beneficial to sustain the positive effects of weight loss following lifestyle changes. This is particularly important if a struggle to maintain weight loss or if weight regain occurs. Pharmacologic therapy can also be considered&#x000a0;alongside&#x000a0;initiating a weight loss program, following a thorough discussion of the risks and benefits with the patients.&#x000a0;</p>
        <p>Drug therapy can&#x000a0;be&#x000a0;considered for individuals with a BMI greater than 30 kg/m or a BMI of 27 to 29.9 kg/m in the presence of weight-related complications. This is especially applicable for patients who have been unable to achieve their weight loss goals (at least 5% of total body weight in 3 to 6 months)&#x000a0;despite&#x000a0;undergoing comprehensive lifestyle intervention. Notably,&#x000a0;initiating drug therapy should always be&#x000a0;coupled with&#x000a0;the&#x000a0;continuation&#x000a0;of behavioral and lifestyle changes. Without this combination, medications&#x000a0;typically yield&#x000a0;low success rates.<xref ref-type="bibr" rid="article-120320.r18">[18]</xref><xref ref-type="bibr" rid="article-120320.r19">[19]</xref></p>
        <p>Approved medications facilitate&#x000a0;weight loss&#x000a0;by decreasing appetite and hunger, increasing satiety, and reducing caloric absorption or intake. Nevertheless, achieving long-term weight maintenance and overcoming the physiologic trend of regaining weight remains a significant challenge.</p>
        <p>When considering the initiation of pharmacologic therapy, an individualized approach is necessary,&#x000a0;factoring&#x000a0;in the patient's&#x000a0;comorbidities, preferences, insurance coverage, and costs. Generally, single agents are preferred over combination therapy. However, different medications can&#x000a0;be&#x000a0;combined to&#x000a0;enhance the response, provided the clinician carefully evaluates safety and interaction profiles.<xref ref-type="bibr" rid="article-120320.r20">[20]</xref></p>
        <p>In clinical studies of weight loss medications, a 5% to 10% reduction in body weight has traditionally been considered significant. This percentage aligns with the FDA's recommendations in trials and is linked to notable clinical improvements in metabolic risk profiles.<xref ref-type="bibr" rid="article-120320.r21">[21]</xref>&#x000a0;Additionally, secondary weight loss outcomes in these trials have&#x000a0;examined the proportion of individuals&#x000a0;achieving a 10% or&#x000a0;greater weight loss and changes in weight from baseline.<xref ref-type="bibr" rid="article-120320.r21">[21]</xref>&#x000a0;</p>
        <p>Obesity medication therapy goals&#x000a0;must be realistic to prevent frustration and treatment discontinuation.&#x000a0;The focus should be on&#x000a0;short-term and&#x000a0;long-term weight reduction, preventing weight gain, improving health parameters, and&#x000a0;managing&#x000a0;side effects.<xref ref-type="bibr" rid="article-120320.r22">[22]</xref>&#x000a0;When starting weight loss therapy, it is&#x000a0;crucial to emphasize that drug responses and side effects can vary significantly among patients. Moreover, patients should be informed that reaching a plateau after initial weight loss is common, and if drug treatment is interrupted, weight regain can be expected.</p>
        <p>
<bold>Semaglutide</bold>
</p>
        <p>Marketed&#x000a0;under Ozempic, Rybelsus, and Wegovy, semaglutide is the&#x000a0;latest&#x000a0;long-acting glucagon-like peptide-1 receptor agonist&#x000a0;(GLP-1RA) approved by the Food and Drug Administration (FDA) for obesity treatment. It has&#x000a0;shown significant weight loss benefits in patients with and without diabetes, along with improvements in glycemic control.&#x000a0;While oral and injectable forms are FDA-approved for diabetes treatment and have&#x000a0;demonstrated weight loss effects, only the subcutaneous preparation has received FDA approval specifically for obesity treatment.<xref ref-type="bibr" rid="article-120320.r15">[15]</xref></p>
        <p>Several studies have&#x000a0;demonstrated the&#x000a0;effectiveness&#x000a0;of semaglutide in promoting weight loss among&#x000a0;individuals who are overweight or obese,&#x000a0;irrespective of whether they have type 2 diabetes.</p>
        <p>In the STEP 1 trial, 1961 adults without diabetes and with obesity (BMI &#x02265;30 kg/m2 or &#x02265;27&#x000a0;kg/m2 with at least&#x000a0;1 weight-related comorbidity) participated in a randomized controlled trial. Patients were assigned to 68 weeks of therapy with weekly&#x000a0;subcutaneous&#x000a0;2.4 mg semaglutide or placebo.&#x000a0;Individuals in the semaglutide group&#x000a0;experienced a significant weight loss of&#x000a0;15.3 kg&#x000a0;compared to&#x000a0;2.6 kg in the placebo group. The estimated treatment difference was 12.7 kg, 95% CI -13.7 to -11.7 kg. More patients in the semaglutide group had weight loss greater than or equal to 5 (86.4% versus 31.5%), greater than or equal to 10 (69.1% versus 12.0%), and greater than or equal to 15 (50.5% versus 4.9%) compared to the placebo group.<xref ref-type="bibr" rid="article-120320.r15">[15]</xref></p>
        <p>In the STEP 2 trial, over 1200 patients with type 2 diabetes and obesity were randomized to receive weekly semaglutide doses of 1 mg and 2.4 mg and compared to a placebo. The estimated treatment difference for semaglutide 2.4 mg (-9.6%) versus placebo (-3.4%) was &#x02212;6.2 percentage points&#x000a0;(95% CI &#x02212;7&#x000b7;3 to &#x02212;5&#x000b7;2; p&#x0003c;0&#x000b7;0001).<xref ref-type="bibr" rid="article-120320.r23">[23]</xref></p>
        <p>Semaglutide&#x000a0;shares&#x000a0;a similar side effect profile&#x000a0;with other GLP-1 agonist agents, including symptoms such as nausea and vomiting. Patients are advised to report any persistent or severe side effects to their healthcare&#x000a0;professional promptly to ensure proper guidance and adjustment of the treatment plan if necessary.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dosing</bold>
<list list-type="bullet"><list-item><p>The injectable formulation of semaglutide includes subcutaneous weekly injections, starting with an initial dose of 0.25 mg for 4 weeks, followed by incremental increases every 4 weeks (0.5, 1.17, 2.4 mg) until reaching the maximum tolerated dose.</p></list-item><list-item><p>In patients with type 2 diabetes, glycemic levels should also be monitored before titration, and dosing of other concomitant hypoglycemic agents should be adjusted to prevent hypoglycemia.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contraindication</bold>
<list list-type="bullet"><list-item><p>Individuals&#x000a0;with a personal history of pancreatitis or a personal or familial history of medullary thyroid cancer or multiple endocrine neoplasia (MEN) 2A or 2B should&#x000a0;avoid semaglutide. Patients should be&#x000a0;educated about the symptoms of pancreatitis or gallbladder pathologies.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Similar to&#x000a0;other GLP-1 agonists, semaglutide has also been shown to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease.<xref ref-type="bibr" rid="article-120320.r24">[24]</xref></p>
        <p>
<bold>Liraglutide</bold>
</p>
        <p>Liraglutide&#x000a0;was the first GLP-1RA to&#x000a0;receive approval for&#x000a0;treating&#x000a0;obesity in patients without diabetes. Subsequently, in 2021, Semaglutide became the second GLP-1RA to be approved for obesity treatment, extending its use to all patients without requiring a diabetes diagnosis.</p>
        <p>Glucagon-like peptide (GLP-1), an incretin peptide secreted by the gut&#x000a0;after&#x000a0;oral food intake, plays a significant role. It inhibits gastric emptying and glucagon release&#x000a0;while inducing glucose-dependent insulin release from the pancreas's beta cells. The GLP-1RAs&#x000a0;are considered a second or third&#x000a0;option&#x000a0;in&#x000a0;treating type 2 diabetes when glycemic control is not achieved. Particularly beneficial for patients with diabetes who are overweight or obese, GLP-1RAs, along with sodium-glucose cotransporter 2 (SGLT2) inhibitors,&#x000a0;are ideal&#x000a0;due to their proven weight loss effects.&#x000a0;Notably, in patients without diabetes, the use of SGLT2 inhibitors for weight loss is still off-label.&#x000a0;</p>
        <p>For obesity treatment, the GLP-1RAs are approved at higher doses than&#x000a0;those recommended for diabetes treatment. They are approved for obesity treatment in adults with a BMI greater than or equal to 30 kg/m&#x000a0;or with a BMI greater than or equal to 27 kg/m when at least&#x000a0;1 weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, osteoarthritis) is present. Liraglutide, approved for obesity,&#x000a0;has a daily dose of 3 mg,&#x000a0;although&#x000a0;an initial dose of 1.2 mg can&#x000a0;yield&#x000a0;weight loss and can be escalated based on tolerability. Semaglutide, approved for obesity,&#x000a0;comes in a convenient 2.4 mg once-weekly dosage. Often, patients achieve weight loss below the maximum dose, experiencing fewer side effects and maintaining adequate glucose control.&#x000a0;</p>
        <p>Randomized controlled trials have&#x000a0;demonstrated liraglutide's efficacy in diabetes management and weight loss.&#x000a0;Multiple studies have&#x000a0;shown sustained weight loss and additional cardiovascular benefits over a maximum duration of 2 years.&#x000a0;</p>
        <p>In a 20-week study&#x000a0;involving&#x000a0;564 patients, liraglutide&#x000a0;at&#x000a0;4 different daily doses (1.2, 1.8, 2.4, and 3 mg) showed&#x000a0;dose-dependent weight loss compared to placebo or open-label orlistat, with weight losses of 5.8 kg and 3.8 kg more than placebo and orlistat, respectively.&#x000a0;These results were consistent in a&#x000a0;2-year extension study, where patients on higher doses (2.4 mg and 3.0 mg)&#x000a0;maintained a weight loss of 7.8 kg at the end of the study (total n=92 patients&#x000a0;on the higher doses). Notably, liraglutide 3.0 mg also substantially reduced body fat by 15.4% while preserving lean tissue, which decreased by only 2.0%.&#x000a0;Moreover, the prevalence of prediabetes and metabolic syndrome&#x000a0;was reduced by 52% and 59%, respectively, after 2 years, accompanied by improved blood pressure and lipid levels.<xref ref-type="bibr" rid="article-120320.r25">[25]</xref></p>
        <p>In a 56-week trial&#x000a0;involving 3731 patients with a BMI greater than or equal to 30 kg/m&#x000a0;or greater than or equal to 27 kg/m&#x000a0;with dyslipidemia or hypertension, liraglutide 3 mg was compared with a placebo. The results demonstrated a mean weight loss&#x000a0;of&#x000a0;8.0 kg versus 2.6 kg&#x000a0;in the placebo group. Additionally, liraglutide improved several cardiometabolic risk factors, glycated hemoglobin (HgbA1C) levels, and quality of life.<xref ref-type="bibr" rid="article-120320.r26">[26]</xref></p>
        <p>The LEADER trial showed that liraglutide, even at a lower dose than the recommended dosage for obesity&#x000a0;(1.8 mg versus 3 mg), reduced major cardiovascular events, including cardiovascular-related deaths, nonfatal myocardial infarction, or nonfatal stroke, in patients with type 2 diabetes.<xref ref-type="bibr" rid="article-120320.r27">[27]</xref>&#x000a0;However, there is currently no available cardiovascular outcome data for patients with obesity&#x000a0;who do not have diabetes.&#x000a0;&#x000a0;</p>
        <p>The primary side effects of liraglutide are mainly gastrointestinal, including&#x000a0;nausea and vomiting,&#x000a0;often more pronounced at the beginning of therapy or after dose increments. The symptoms appear to be dose-dependent. Sometimes, selecting an&#x000a0;intermediate dose that patients can tolerate while&#x000a0;preserving the medication's positive effects may be a practical approach.</p>
        <p>While&#x000a0;there is an observed finding of pancreatitis, a definitive causal relationship has not been established. Furthermore, gallbladder&#x000a0;disease can predispose to cholelithiasis, and persistent nausea and vomiting can lead to dehydration&#x000a0;if the medication is not discontinued.<xref ref-type="bibr" rid="article-120320.r27">[27]</xref>&#x000a0;Liraglutide has&#x000a0;demonstrated&#x000a0;an association with&#x000a0;malignant medullary carcinoma in rodent trials; however, this&#x000a0;correlation remains unproven in humans.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dosing</bold>
<list list-type="bullet"><list-item><p>Liraglutide is administered subcutaneously, starting with an initial dose of 0.6 mg daily for&#x000a0;1 week,&#x000a0;followed by weekly increment increases of 0.6 mg until reaching the recommended dose of 3 mg.</p></list-item><list-item><p>While many patients cannot tolerate the highest dose, they can still experience benefits&#x000a0;at lower dosages within their maximum tolerance level.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contraindications&#x000a0;</bold>
<list list-type="bullet"><list-item><p>Several&#x000a0;other GLP-1 receptor agonists with similar responses in glucose control, weight loss, and cardiovascular benefits have entered the market. However,&#x000a0;these medications&#x000a0;have not&#x000a0;obtained approval for treating overweight or obese patients without diabetes.</p></list-item><list-item><p>Researchers have not studied the medication's effects during pregnancy,&#x000a0;making it contraindicated in pregnant individuals. It is also not recommended for patients with a personal or family history of medullary thyroid cancer or&#x000a0;MEN 2A or 2B.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Semaglutide and liraglutide were compared in a randomized controlled trial (STEP 8) which included 338 adults with a BMI greater than or equal to 30 kg/m&#x000b2; (or &#x02265;27 kg/m&#x000b2; with &#x02265;1 weight-related comorbidity) assigned to once-weekly subcutaneous semaglutide 2.4 mg or placebo), or once-daily subcutaneous 3.0 mg liraglutide, or placebo. At the end of 68 weeks, participants in the semaglutide group&#x000a0;demonstrated&#x000a0;greater weight loss than the liraglutide group (-15.8% versus -6.4%; treatment difference -9.4% [95% CI -12.0 to -6.8]). In contrast, the weight change in the placebo group was -1.9 percent.&#x000a0;Additionally, the semaglutide group&#x000a0;exhibited a higher percentage of individuals achieving 10%, 15%, or 20% or more weight loss&#x000a0;<xref ref-type="bibr" rid="article-120320.r28">[28]</xref>.</p>
        <p>
<bold>Orlistat </bold>
</p>
        <p>Orlistat functions by inhibiting pancreatic lipases, disrupting fat digestion in the gut. Consequently, fat molecules are not fully hydrolyzed and remain unabsorbed. The extent of weight loss correlates with the calories lost&#x000a0;through fecal fat excretion, representing up to a 30% reduction in calorie intake on an average diet.</p>
        <p>Several studies, including randomized control trials and meta-analyses, have demonstrated the efficacy of orlistat.<xref ref-type="bibr" rid="article-120320.r29">[29]</xref><xref ref-type="bibr" rid="article-120320.r30">[30]</xref>&#x000a0;In a meta-analysis of 12 trials, the orlistat group&#x000a0;exhibited a mean&#x000a0;weight loss of 8%, in contrast to 5%&#x000a0;in the placebo group, even with&#x000a0;comparable behavioral&#x000a0;interventions.<xref ref-type="bibr" rid="article-120320.r31">[31]</xref>&#x000a0;Furthermore, subjects were able to&#x000a0;sustain their weight loss with continuous therapy for up to 24 to 36 months.&#x000a0;&#x000a0;</p>
        <p>In the Xendos study, 3304 patients who were overweight were randomly assigned to orlistat or placebo. Notably, 21% of these patients had impaired glucose tolerance.&#x000a0;Over the first year, researchers observed a substantial disparity between groups, with the orlistat group experiencing an 11% reduction from baseline, compared to 6% in the placebo group. Although this&#x000a0;gap narrowed&#x000a0;during the&#x000a0;subsequent&#x000a0;3 years of the trial, the orlistat group&#x000a0;maintained a 6.9% reduction&#x000a0;from&#x000a0;baseline, while the placebo showed&#x000a0;a 4.1% reduction. Despite the diminished difference by the study's end, patients in the orlistat group had a lower incidence of diabetes than the placebo group (6.2% versus&#x000a0;9%). In trials involving patients with diabetes, orlistat also&#x000a0;led to greater weight loss and lower HgbA1c levels at 1&#x000a0;year compared to the placebo groups.<xref ref-type="bibr" rid="article-120320.r32">[32]</xref></p>
        <p>Additional&#x000a0;benefits of orlistat have been&#x000a0;observed in&#x000a0;various studies. A systematic review highlighted a decrease in systolic and diastolic blood pressure in individuals taking prlistat compared to placebo (with a weighted difference of -2.5 and -1.9 mm Hg, respectively).<xref ref-type="bibr" rid="article-120320.r33">[33]</xref>&#x000a0;Moreover, in a multicenter trial, orlistat&#x000a0;demonstrated&#x000a0;improvements in serum lipid values,&#x000a0;including a 5% to 10% reduction in&#x000a0;low-density lipoprotein (LDL) cholesterol in patients treated with orlistat and a low-fat diet&#x000a0;over 48 weeks from baseline.<xref ref-type="bibr" rid="article-120320.r34">[34]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dosing:</bold>
<list list-type="bullet"><list-item><p>The recommended dose is 120 mg, taken 3 times daily,&#x000a0;accompanying&#x000a0;each meal.</p></list-item><list-item><p>Patients are strongly advised to take a daily multivitamin at bedtime to compensate for the reduced absorption of fat-soluble vitamins associated with chronic orlistat use.</p></list-item><list-item><p>This medication is available over the counter in many countries,&#x000a0;including the United States.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contraindications</bold>:
<list list-type="bullet"><list-item><p>Patients can&#x000a0;utilize orlistat for up to 4 years in&#x000a0;obesity treatment. If therapy&#x000a0;extends beyond this period, it is essential to discuss it with the patient, informing them about the absence of&#x000a0;extended studies.&#x000a0;</p></list-item><list-item><p>The medication has not&#x000a0;undergone&#x000a0;studies in pregnant individuals and&#x000a0;should not be considered&#x000a0;for patients with chronic malabsorption, cholestasis, or calcium oxalate stones.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Commonly observed side effects of orlistat are<bold>&#x000a0;</bold>gastrointestinal, including abdominal cramps, increased flatulence, and fecal incontinence. These effects are more prevalent&#x000a0;early in its use and&#x000a0;often diminish&#x000a0;when patients adhere to a low-fat diet (&#x0003c;30%) without&#x000a0;compromising weight loss benefits.<xref ref-type="bibr" rid="article-120320.r35">[35]</xref>&#x000a0;Although the FDA&#x000a0;recorded 13 instances&#x000a0;of severe liver injury,&#x000a0;establishing a&#x000a0;direct cause&#x000a0;has proven challenging due to patients&#x000a0;concurrently taking other medications and having underlying medical conditions that could contribute to such incidents. However, individuals using orlistat should understand&#x000a0;the need to contact their healthcare&#x000a0;professional if signs or symptoms of liver injury occur. There&#x000a0;is no&#x000a0;heightened&#x000a0;risk of cholelithiasis, cardiovascular issues, or psychiatric events associated with orlistat usage.&#x000a0;</p>
        <p>Orlistat's mechanism of fat fecal excretion can impair the levels of fat-soluble vitamins (A, D, E, K) and&#x000a0;beta-carotene. Additionally, it can prolong the international normalized ratio (INR) and prothrombin time in patients taking warfarin by reducing vitamin K levels, requiring a reduction of warfarin&#x000a0;dosage and&#x000a0;careful monitoring.<xref ref-type="bibr" rid="article-120320.r36">[36]</xref></p>
        <p>Fat malabsorption leads to the binding of enteric calcium with fat excreted in stools. Consequently, intestinal oxalate becomes more&#x000a0;accessible for&#x000a0;absorption and subsequent excretion in the urine. Excessive free oxalate can&#x000a0;accumulate in the renal parenchyma, potentially resulting in acute nephrocalcinosis and acute kidney injury.<xref ref-type="bibr" rid="article-120320.r37">[37]</xref></p>
        <p>
<bold>Combination therapies</bold>
</p>
        <p>Given the chronic&#x000a0;nature of&#x000a0;obesity&#x000a0;requiring&#x000a0;prolonged treatment and the potential side effects associated with various medications, combination&#x000a0;therapies have been suggested as a more practical approach. This involves using lower doses of&#x000a0;2 medications, allowing 1 drug to offset the potential&#x000a0;side effects of the other&#x000a0;while maximizing their efficacy.&#x000a0;</p>
        <p>
<bold>Phentermine-topiramate combination</bold>
</p>
        <p>In 2012, the FDA approved the combination of phentermine-topiramate for adults with a BMI of 30 kg/m&#x000b2;&#x000a0;or greater or with a BMI of 27 kg/m&#x000b2; or less with at least&#x000a0;1 weight-related comorbidity (eg, hypertension, diabetes, dyslipidemia)&#x000a0;to be used alongside reduced dietary caloric intake for weight loss. It is not&#x000a0;advisable for patients with a high cardiovascular risk due to a potential increase in heart rate; however, a 2-year trial&#x000a0;did not show an elevated&#x000a0;mortality compared to the placebo group. Long-term data on mortality is currently&#x000a0;unavailable.&#x000a0;This combination&#x000a0;can be&#x000a0;considered as the&#x000a0;initial option in obesity treatment, especially for&#x000a0;patients who did not tolerate or failed liraglutide or orlistat, particularly those with binge eating disorder.&#x000a0;</p>
        <p>In the Conquer trial involving 2487 patients, there was a change in body weight of -1.4 kg in the placebo group versus -8.1 in the phentermine-topiramate (7.5/46 mg) group after 56 weeks.<xref ref-type="bibr" rid="article-120320.r38">[38]</xref>&#x000a0;In&#x000a0;the extension study (Sequel) that followed patients for&#x000a0;an additional 52 weeks,&#x000a0;patients&#x000a0;on the low dose of phentermine-topiramate achieved a mean weight loss of 9.6 kg versus 2.1 kg in the placebo group after 108 weeks from the original baseline.<xref ref-type="bibr" rid="article-120320.r39">[39]</xref>&#x000a0;Although the weight loss in the second year was less pronounced,&#x000a0;most participants could maintain their weight loss,&#x000a0;while the placebo group&#x000a0;experienced a slight increase in body weight.&#x000a0;Notably, all&#x000a0;individuals were simultaneously participating in a lifestyle modification program.&#x000a0;</p>
        <p>Participants in the phentermine-topiramate group&#x000a0;exhibited&#x000a0;improved cardiovascular and metabolic variables and a lower incidence of diabetes than&#x000a0;the placebo group.&#x000a0;The combination&#x000a0;remained tolerated over 108 weeks, with adverse events occurring more frequently in the initial trial phase.&#x000a0;</p>
        <p>The most commonly reported side effects of the medication&#x000a0;include paraesthesias, dizziness, dysgeusia, insomnia, constipation, and dry mouth. Patients in the medication-treated groups&#x000a0;experienced a slight reduction in blood pressure, accompanied by a slight increase in heart rate of 1.3 and 1.7 bpm for low and high doses, respectively, versus 0.4 in the placebo group. However, there were no reported adverse events related to the increase in heart rate.&#x000a0;</p>
        <p>Regarding psychiatric side effects, there was no increase in severe suicidal ideation or behavior among participants during the 108 weeks of observation. Reports of dose-dependent anxiety-related&#x000a0;adverse events were noted (3.1%, 6.5%, and 9.5% for placebo, 7.5/46 mg, and 15/92 mg arms, respectively), but they were mostly of mild severity.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dosing:&#x000a0;</bold>There are&#x000a0;4 different fixed drug combinations for the phentermine-topiramate combination.
<list list-type="bullet"><list-item><p>The starting dose is 3.75/23 mg for 14 days, which should then be increased to the recommended 7.5/46 mg dose.</p></list-item><list-item><p>If, after 12 weeks of treatment, a 3% loss of baseline body weight does not occur, the recommendation is to&#x000a0;escalate the dose to 11.25/69 mg for another 14 days and then to 15/92 mg after that.</p></list-item><list-item><p>If &#x0003c;5% of body weight is achieved after 12 weeks on the highest dose, the medication should be gradually discontinued to avoid withdrawal symptoms from topiramate.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contraindications:</bold>
<list list-type="bullet"><list-item><p>The phentermine-topiramate combination is contraindicated during pregnancy due to teratogenicity, posing a risk of orofacial clefts in infants exposed to the medication during the first trimester of pregnancy.&#x000a0;Therefore, it is mandatory to obtain a pregnancy test before&#x000a0;initiating the drug in childbearing-age females and then monthly after that.</p></list-item><list-item><p>Additionally, the combination should not be used in patients with hyperthyroidism or acute angle glaucoma and&#x000a0;is not recommended for individuals who have taken&#x000a0;monoamine oxidase inhibitors in the past 14 days.</p></list-item><list-item><p>Caution is advised in patients with a history of kidney stones due to the increased risk related to topiramate.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Recommended monitoring includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Heart rate&#x000a0;assessment at every visit.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Regular screening for suicidal behavior and ideation, with discontinuation of the drug if symptoms develop.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monitoring for visual disturbances, especially acute myopia, and signs of increased intraocular pressure.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Evaluation of cognitive&#x000a0;function&#x000a0;due to potential disturbances in attention or memory caused by&#x000a0;topiramate.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Periodic checks of electrolytes&#x000a0;and&#x000a0;creatinine before and during treatment,&#x000a0;as topiramate inhibits carbonic anhydrase enzyme, predisposing&#x000a0;individuals to acidosis, although significant acidosis has not been reported in the trials.</p>
          </list-item>
        </list>
        <p>Phentermine can also serve as a monotherapy in the short-term treatment of obesity. It is FDA-approved&#x000a0;for use over a few weeks, coupled with&#x000a0;exercise, behavioral modification, and caloric restriction, specifically for patients with a BMI of 30 kg/m or greater or 27 kg/m2 or less in the presence of additional risk factors, such as controlled hypertension, diabetes, hyperlipidemia.</p>
        <p>Phentermine suppresses appetite and induces early satiety, commonly prescribed as monotherapy. A notable study, conducted in 1968 over 36 weeks, assessed continuous and intermittent administration of phentermine,&#x000a0;resulting in more significant weight loss than the&#x000a0;placebo (-12.2 and -13.0 kg for continuous and intermittent use, respectively, versus -4.8 kg in the placebo group).<xref ref-type="bibr" rid="article-120320.r40">[40]</xref></p>
        <p>In the category of sympathomimetic drugs, sibutramine was withdrawn from the US and European markets in 2010&#x000a0;following the SCOUT study, which revealed a 16%&#x000a0;rise in the incidence of cardiovascular events (comprising nonfatal heart attack, nonfatal stroke, resuscitation after cardiac arrest, and cardiovascular death)&#x000a0;among patients&#x000a0;treated with the drug&#x000a0;compared to the&#x000a0;placebo group (more details on section "issues of concern").&#x000a0;</p>
        <p>
<bold>Naltrexone-bupropion</bold>
</p>
        <p>Although no head-to-head studies comparing this combination therapy and phentermine-topiramate are available,&#x000a0;the outcomes from&#x000a0;published trials suggest its lower efficacy compared to the previously mentioned treatment. Consequently,&#x000a0;it is not recommended as the primary pharmacologic therapy for managing obesity.</p>
        <p>The naltrexone-bupropion combination&#x000a0;serves as a&#x000a0;viable option, particularly beneficial for individuals aiming to quit&#x000a0;smoking while addressing&#x000a0;weight concerns. Although this combination's precise weight loss mechanism is not fully understood, it is theorized that they&#x000a0;synergistically impact hunger centers in the hypothalamus and the mesolimbic dopamine circuit.</p>
        <p>Bupropion, functioning as a weak dopamine and norepinephrine reuptake inhibitor, stimulates pro-opiomelanocortin (POMC) production and the release of alpha-MSH and beta-endorphin,&#x000a0;an endogenous opioid, in vitro. Alpha-MSH activates the&#x000a0;melanocortin-4 receptor (MC4R),&#x000a0;contributing to reduced food intake,&#x000a0;increased energy expenditure, and subsequent weight loss. However,&#x000a0;with&#x000a0;sustained bupropion intake,&#x000a0;beta-endorphin's&#x000a0;down-regulatory effect on POMC cells is initiated through binding to the inhibitory mu-opioid receptor.&#x000a0;Naltrexone, an opioid antagonist, counteracts this effect by blocking the&#x000a0;mu-opioid receptor, disrupting the beta-endorphins inhibitory feedback on POMC cells.<xref ref-type="bibr" rid="article-120320.r41">[41]</xref><xref ref-type="bibr" rid="article-120320.r42">[42]</xref>&#x000a0;&#x000a0;</p>
        <p>FDA approved the&#x000a0;combination&#x000a0;drug in September 2014&#x000a0;for weight loss, diet, and exercise for patients with a BMI of 30 kg/m or greater or 27 kg/m or less&#x000a0;with&#x000a0;at least&#x000a0;1 weight-related comorbidity. This medication offers a valuable option for individuals struggling with obesity, particularly those seeking a comprehensive approach to weight management.</p>
        <p>In a multicenter randomized trial, the combination&#x000a0;resulted in a -6.1% reduction in body weight versus -1.3% in the placebo group, with only 50% of participants completing the 56 weeks of treatment. While&#x000a0;mean weight loss was greater with combination therapy than with placebo, there were significant increases in mean blood pressure and heart rate reductions in the placebo group (-2.1/2.8 versus 0.2/-0.4 mmHg and -0.1 versus 1.5 beats per minute).</p>
        <p>The naltrexone-bupropion combination commonly causes nausea, headache, and constipation. The FDA&#x000a0;advises&#x000a0;monitoring patients for suicidal behavior and ideation, the risk of seizure due to bupropion lowering the seizure threshold, an increase in blood pressure and heart rate, hepatotoxicity observed with naltrexone exposure, and angle-closure glaucoma.</p>
        <p>Clinicians&#x000a0;are advised to refrain from prescribing the drug to patients&#x000a0;with high cardiovascular risk due to the observed increase in heart rate and blood pressure. A cardiovascular safety trial was interrupted in the initial phase due to a breach of confidentiality, but preliminary data showed reduced cardiovascular events. However, the issue remains controversial due to the lack of study completion.&#x000a0;The medication received approval with a warning for increased blood pressure and heart rate, but the cardiovascular risk was inconclusive.<xref ref-type="bibr" rid="article-120320.r43">[43]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dosing:</bold>&#x000a0;
<list list-type="bullet"><list-item><p>The initial dose is&#x000a0;1 tablet daily&#x000a0;containing&#x000a0;8 mg of&#x000a0;naltrexone and 90 mg of bupropion.</p></list-item><list-item><p>If tolerated, the dose should increase to&#x000a0;1 tablet twice daily after the first week and 2 tablets twice daily in the fourth week.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contraindications:</bold>
<list list-type="bullet"><list-item><p>Pregnancy</p></list-item><list-item><p>Uncontrolled hypertension</p></list-item><list-item><p>Seizure disorder</p></list-item><list-item><p>Eating disorder</p></list-item><list-item><p>Use of other bupropion-containing products</p></list-item><list-item><p>Chronic opioid use</p></list-item><list-item><p>Use of monoamine oxidase inhibitors in the previous 14 days</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-120320.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>To date,&#x000a0;several pharmacotherapy options for obesity exist, although&#x000a0;they are not a definitive solution to the problem.&#x000a0;While they have demonstrated positive outcomes in enhancing&#x000a0;cardiometabolic parameters, some may have undesirable side effects. Predicting individual responses and tolerance remains challenging.</p>
        <p>Several&#x000a0;anti-obesity drugs have been withdrawn from the market due to significant side effects. Currently, the only approved drugs in the US are orlistat, liraglutide, semaglutide, phentermine-topiramate, phentermine alone, and bupropion-naloxone. Sibutramine was withdrawn more than ten years ago, and lorcaserin was removed more recently due to an increased risk of various types of cancer.</p>
        <p>The currently approved medications lack long-term safety studies.&#x000a0;Given&#x000a0;the lack of longer-term studies,&#x000a0;significant adverse effects, limited efficacy, and warnings over the safety of medicines,&#x000a0;healthcare practitioners&#x000a0;need to emphasize&#x000a0;that obesity is a chronic condition requiring lifelong monitoring. This should be accompanied by a low-calorie diet, regular physical activity, and the support of a multidisciplinary team, including a dietician, primary care provider, endocrinologist, and, when necessary, psychiatrist or therapist. Bariatric surgery should also&#x000a0;be&#x000a0;considered as an option for patients with refractory obesity who have&#x000a0;exhausted other medical therapies or who&#x000a0;face complications from obesity.&#x000a0;Evaluation by a behavioral therapist&#x000a0;is crucial to&#x000a0;rule out binge eating disorder or other compulsive disorders.&#x000a0;</p>
      </sec>
      <sec id="article-120320.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=120320&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=120320">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/120320/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=120320">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-120320.s7">
        <title>References</title>
        <ref id="article-120320.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Global BMI Mortality Collaboration</surname>
              </name>
              <name>
                <surname>Di Angelantonio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bhupathiraju</surname>
                <given-names>ShN</given-names>
              </name>
              <name>
                <surname>Wormser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaptoge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berrington de Gonzalez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cairns</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Huxley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>ChL</given-names>
              </name>
              <name>
                <surname>Joshy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lewington</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Samet</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barricarte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Halsey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hildebrand</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Korda</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McLerran</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>O'Keeffe</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Paige</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramond</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Rolland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sacerdote</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sofianopoulou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ueshima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Willeit</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beral</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Zh</given-names>
              </name>
              <name>
                <surname>Gapstur</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gunter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Danesh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>FB</given-names>
              </name>
            </person-group>
            <article-title>Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Aug</month>
            <day>20</day>
            <volume>388</volume>
            <issue>10046</issue>
            <fpage>776</fpage>
            <page-range>776-86</page-range>
            <pub-id pub-id-type="pmid">27423262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torgerson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Swedish Obese Subjects (SOS) study--rationale and results.</article-title>
            <source>Int J Obes Relat Metab Disord</source>
            <year>2001</year>
            <month>May</month>
            <volume>25 Suppl 1</volume>
            <fpage>S2</fpage>
            <page-range>S2-4</page-range>
            <pub-id pub-id-type="pmid">11466577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelaal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>le Roux</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Docherty</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Morbidity and mortality associated with obesity.</article-title>
            <source>Ann Transl Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>161</fpage>
            <pub-id pub-id-type="pmid">28480197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apovian</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Aronne</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bessesen</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>McDonnell</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pagotto</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Still</surname>
                <given-names>CD</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Pharmacological management of obesity: an endocrine Society clinical practice guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>342</fpage>
            <page-range>342-62</page-range>
            <pub-id pub-id-type="pmid">25590212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esteghamati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazaheri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vahidi Rad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noshad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Complementary and alternative medicine for the treatment of obesity: a critical review.</article-title>
            <source>Int J Endocrinol Metab</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>e19678</fpage>
            <pub-id pub-id-type="pmid">25892995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Venter</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bertram</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Human chorionic gonadotrophin and weight loss. A double-blind, placebo-controlled trial.</article-title>
            <source>S Afr Med J</source>
            <year>1990</year>
            <month>Feb</month>
            <day>17</day>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>185</fpage>
            <page-range>185-9</page-range>
            <pub-id pub-id-type="pmid">2405506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Caterson</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Finer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Rode</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Renz</surname>
                <given-names>CL</given-names>
              </name>
              <collab>SCOUT Investigators</collab>
            </person-group>
            <article-title>Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Sep</month>
            <day>02</day>
            <volume>363</volume>
            <issue>10</issue>
            <fpage>905</fpage>
            <page-range>905-17</page-range>
            <pub-id pub-id-type="pmid">20818901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Magnano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weimer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heymsfield</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leibel</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight.</article-title>
            <source>J Clin Invest</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>115</volume>
            <issue>12</issue>
            <fpage>3579</fpage>
            <page-range>3579-86</page-range>
            <pub-id pub-id-type="pmid">16322796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Leibel</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>906</fpage>
            <page-range>906-12</page-range>
            <pub-id pub-id-type="pmid">18842775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mabire</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The Influence of Age, Sex and Body Mass Index on the Effectiveness of Brisk Walking for Obesity Management in Adults: A Systematic Review and Meta-Analysis.</article-title>
            <source>J Phys Act Health</source>
            <year>2017</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>389</fpage>
            <page-range>389-407</page-range>
            <pub-id pub-id-type="pmid">28169568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>Diabetes Prevention Program Research Group</collab>
            <article-title>Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>866</fpage>
            <page-range>866-75</page-range>
            <pub-id pub-id-type="pmid">26377054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Look AHEAD Research Group</collab>
              <name>
                <surname>Wing</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Bolin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brancati</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Coday</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crow</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Espeland</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Foreyt</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ghazarian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gregg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hazuda</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Jakicic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jeffery</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kitabchi</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Knowler</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Maschak-Carey</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Montez</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Murillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Patricio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pi-Sunyer</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pownall</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reboussin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Regensteiner</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rickman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Safford</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wagenknecht</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Yanovski</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Jul</month>
            <day>11</day>
            <volume>369</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-54</page-range>
            <pub-id pub-id-type="pmid">23796131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dansinger</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gleason</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Selker</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial.</article-title>
            <source>JAMA</source>
            <year>2005</year>
            <month>Jan</month>
            <day>05</day>
            <volume>293</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-53</page-range>
            <pub-id pub-id-type="pmid">15632335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trepanowski</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kroeger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Barnosky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klempel</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bhutani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoddy</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Gabel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Freels</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rigdon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ravussin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Varady</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults: A Randomized Clinical Trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>177</volume>
            <issue>7</issue>
            <fpage>930</fpage>
            <page-range>930-938</page-range>
            <pub-id pub-id-type="pmid">28459931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilding</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Batterham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Calanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>MTD</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zeuthen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <collab>STEP 1 Study Group</collab>
            </person-group>
            <article-title>Once-Weekly Semaglutide in Adults with Overweight or Obesity.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Mar</month>
            <day>18</day>
            <volume>384</volume>
            <issue>11</issue>
            <fpage>989</fpage>
            <page-range>989-1002</page-range>
            <pub-id pub-id-type="pmid">33567185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villareal</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Aguirre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gurney</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Sinacore</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Armamento-Villareal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qualls</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>18</day>
            <volume>376</volume>
            <issue>20</issue>
            <fpage>1943</fpage>
            <page-range>1943-1955</page-range>
            <pub-id pub-id-type="pmid">28514618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piercy</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Troiano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Fulton</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Galuska</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The Physical Activity Guidelines for Americans.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Nov</month>
            <day>20</day>
            <volume>320</volume>
            <issue>19</issue>
            <fpage>2020</fpage>
            <page-range>2020-2028</page-range>
            <pub-id pub-id-type="pmid">30418471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanovski</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Yanovski</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Long-term drug treatment for obesity: a systematic and clinical review.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Jan</month>
            <day>01</day>
            <volume>311</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-86</page-range>
            <pub-id pub-id-type="pmid">24231879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Apovian</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Comuzzie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Jakicic</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Loria</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Millen</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Nonas</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Pi-Sunyer</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Yanovski</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lux</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Mentor-Marcel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Trisolini</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wnek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tomaselli</surname>
                <given-names>GF</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
              <collab>Obesity Society</collab>
            </person-group>
            <article-title>2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Jun</month>
            <day>24</day>
            <volume>129</volume>
            <issue>25 Suppl 2</issue>
            <fpage>S102</fpage>
            <page-range>S102-38</page-range>
            <pub-id pub-id-type="pmid">24222017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Mechanick</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Brett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jastreboff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nadolsky</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pessah-Pollack</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Plodkowski</surname>
                <given-names>R</given-names>
              </name>
              <collab>Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines</collab>
            </person-group>
            <article-title>AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at https://www.aace.com/publications/guidelines.</article-title>
            <source>Endocr Pract</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>842</fpage>
            <page-range>842-84</page-range>
            <pub-id pub-id-type="pmid">27472012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chandar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dulai</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Loomba</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jun</month>
            <day>14</day>
            <volume>315</volume>
            <issue>22</issue>
            <fpage>2424</fpage>
            <page-range>2424-34</page-range>
            <pub-id pub-id-type="pmid">27299618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jinnett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolotkin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nadglowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Stevenin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lille&#x000f8;re</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dhurandhar</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION Study.</article-title>
            <source>Obesity (Silver Spring)</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-69</page-range>
            <pub-id pub-id-type="pmid">29086529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>F&#x000e6;rch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Pakseresht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Perreault</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shimomura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Viljoen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <collab>STEP 2 Study Group</collab>
            </person-group>
            <article-title>Semaglutide 2&#x000b7;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Mar</month>
            <day>13</day>
            <volume>397</volume>
            <issue>10278</issue>
            <fpage>971</fpage>
            <page-range>971-984</page-range>
            <pub-id pub-id-type="pmid">33667417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marso</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Consoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eliaschewitz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>J&#x000f3;dar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seufert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vilsb&#x000f8;ll</surname>
                <given-names>T</given-names>
              </name>
              <collab>SUSTAIN-6 Investigators</collab>
            </person-group>
            <article-title>Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>10</day>
            <volume>375</volume>
            <issue>19</issue>
            <fpage>1834</fpage>
            <page-range>1834-1844</page-range>
            <pub-id pub-id-type="pmid">27633186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Astrup</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carraro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Finer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kunesova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lean</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Niskanen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Rissanen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000f6;ssner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savolainen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>L</given-names>
              </name>
              <collab>NN8022-1807 Investigators</collab>
            </person-group>
            <article-title>Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.</article-title>
            <source>Int J Obes (Lond)</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>843</fpage>
            <page-range>843-54</page-range>
            <pub-id pub-id-type="pmid">21844879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niswender</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Aronne</surname>
                <given-names>L</given-names>
              </name>
              <collab>NN8022-1923 Investigators</collab>
            </person-group>
            <article-title>Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.</article-title>
            <source>Int J Obes (Lond)</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>1443</fpage>
            <page-range>1443-51</page-range>
            <pub-id pub-id-type="pmid">23812094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marso</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Brown-Frandsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Ravn</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Stockner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bergenstal</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <collab>LEADER Steering Committee</collab>
              <collab>LEADER Trial Investigators</collab>
            </person-group>
            <article-title>Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Jul</month>
            <day>28</day>
            <volume>375</volume>
            <issue>4</issue>
            <fpage>311</fpage>
            <page-range>311-22</page-range>
            <pub-id pub-id-type="pmid">27295427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubino</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Greenway</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rrig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wizert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <collab>STEP 8 Investigators</collab>
            </person-group>
            <article-title>Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Jan</month>
            <day>11</day>
            <volume>327</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-150</page-range>
            <pub-id pub-id-type="pmid">35015037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torgerson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hauptman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boldrin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.</article-title>
            <source>Diabetes Care</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-61</page-range>
            <pub-id pub-id-type="pmid">14693982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Maglione</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mojica</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Arterburn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shugarman</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Hilton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Suttorp</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shekelle</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: pharmacologic treatment of obesity.</article-title>
            <source>Ann Intern Med</source>
            <year>2005</year>
            <month>Apr</month>
            <day>05</day>
            <volume>142</volume>
            <issue>7</issue>
            <fpage>532</fpage>
            <page-range>532-46</page-range>
            <pub-id pub-id-type="pmid">15809465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leblanc</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Whitlock</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Patnode</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Kapka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force.</article-title>
            <source>Ann Intern Med</source>
            <year>2011</year>
            <month>Oct</month>
            <day>04</day>
            <volume>155</volume>
            <issue>7</issue>
            <fpage>434</fpage>
            <page-range>434-47</page-range>
            <pub-id pub-id-type="pmid">21969342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelley</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Pi-Sunyer</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.</article-title>
            <source>Diabetes Care</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>1033</fpage>
            <page-range>1033-41</page-range>
            <pub-id pub-id-type="pmid">12032111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siebenhofer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jeitler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Berghold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Posch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meschik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Semlitsch</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Long-term effects of weight-reducing drugs in people with hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Mar</month>
            <day>02</day>
            <volume>3</volume>
            <fpage>CD007654</fpage>
            <pub-id pub-id-type="pmid">26934640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancy</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>McDuffie</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Grambow</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jeffreys</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chalecki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oddone</surname>
                <given-names>EZ</given-names>
              </name>
            </person-group>
            <article-title>A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss.</article-title>
            <source>Arch Intern Med</source>
            <year>2010</year>
            <month>Jan</month>
            <day>25</day>
            <volume>170</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-45</page-range>
            <pub-id pub-id-type="pmid">20101008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Long-term pharmacotherapy for obesity and overweight.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2004</year>
            <volume>2003</volume>
            <issue>3</issue>
            <fpage>CD004094</fpage>
            <pub-id pub-id-type="pmid">15266516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacWalter</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Orlistat enhances warfarin effect.</article-title>
            <source>Ann Pharmacother</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>510</fpage>
            <page-range>510-2</page-range>
            <pub-id pub-id-type="pmid">12659605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gaber</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <page-range>153-7</page-range>
            <pub-id pub-id-type="pmid">17185156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gadde</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Troupin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwiers</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2011</year>
            <month>Apr</month>
            <day>16</day>
            <volume>377</volume>
            <issue>9774</issue>
            <fpage>1341</fpage>
            <page-range>1341-52</page-range>
            <pub-id pub-id-type="pmid">21481449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gadde</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schwiers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Bowden</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>297</fpage>
            <page-range>297-308</page-range>
            <pub-id pub-id-type="pmid">22158731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munro</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>MacCuish</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of continuous and intermittent anorectic therapy in obesity.</article-title>
            <source>Br Med J</source>
            <year>1968</year>
            <month>Feb</month>
            <day>10</day>
            <volume>1</volume>
            <issue>5588</issue>
            <fpage>352</fpage>
            <page-range>352-4</page-range>
            <pub-id pub-id-type="pmid">15508204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Billes</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Greenway</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with naltrexone and bupropion for obesity.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>1813</fpage>
            <page-range>1813-26</page-range>
            <pub-id pub-id-type="pmid">21689063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenway</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Guttadauria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Fujioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gadde</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dunayevich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cowley</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Rational design of a combination medication for the treatment of obesity.</article-title>
            <source>Obesity (Silver Spring)</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-9</page-range>
            <pub-id pub-id-type="pmid">18997675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-120320.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Prcela</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Mar</month>
            <day>08</day>
            <volume>315</volume>
            <issue>10</issue>
            <fpage>990</fpage>
            <page-range>990-1004</page-range>
            <pub-id pub-id-type="pmid">26954408</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
